Brn-2/BRN2/POU3F2 CRISPR Activation Plasmid (m): sc-422351-ACT

Pou3f2 encodes the POU-domain transcription factor Brn-2/BRN2/POU3F2, a key regulator of neural lineage specification and maturation in mouse. BRN2 binds octamer-like DNA motifs to coordinate gene programs controlling neurogenesis, neuronal differentiation, and maintenance of neural identity, integrating with broader transcriptional networks that shape chromatin accessibility and cell-state transitions. In development and adult tissues, Pou3f2 activity influences neural crest–derived and central nervous system lineages, linking it to processes such as progenitor proliferation, migration, and synaptic gene expression. Dysregulated BRN2-associated transcriptional circuits have been studied in contexts including neurodevelopmental phenotypes and lineage plasticity in cancer models, supporting its use as a node for pathway and gene network interrogation.

Brn-2/BRN2/POU3F2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Pou3f2 expression without altering the underlying DNA sequence.

Brn-2/BRN2/POU3F2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Pou3f2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.

Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Pou3f2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Brn-2/BRN2/POU3F2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Pou3f2 locus and enabling the study of Brn-2/BRN2/POU3F2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Brn-2/BRN2/POU3F2 pathway restoration in tumor cells with silenced or reduced Pou3f2 expression.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.